Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22346635 | 0.83 | GPR35 (0.31) | — | |
| SCHEMBL358314 | 0.82 | KDM4E (0.37) | SMN1; SMN2 | |
| SCHEMBL30691793 | 0.82 | NQO2 (0.33) | — | |
| SCHEMBL28718650 | 0.76 | EIF4EBP1 (0.35) | SMN1; SMN2 | |
| SCHEMBL31297581 | 0.75 | RAB9A (0.42) | SMN1; SMN2 | |
| SCHEMBL21813838 | 0.71 | KDM4E (0.43) | SMN1; SMN2 | |
| SCHEMBL21814160 | 0.71 | UGT8 (0.42) | — | |
| SCHEMBL30691590 | 0.71 | NQO2 (0.31) | — | |
| SCHEMBL29560681 | 0.71 | KDM4E (0.43) | SMN1; SMN2 | |
| SCHEMBL16152610 | 0.70 | SMN1; SMN2 (0.31) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382305-A1 | COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC THERAPEUTICS INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12384797-B2 | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia | PTC THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| CN-119997954-A | Compounds for the treatment of spinocerebellar ataxia type 3 | PTC医疗公司 | 2025-05-13 | — | — | CN | disclosed |
| EP-4543444-A1 | COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2023250316-A1 | COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20220135586-A1 | THIOENO[3,2-B] PYRIDIN-7-AMINE COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| EP-3924049-A1 | THIOENO[3,2-B] PYRIDIN-7-AMINE COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC Therapeutics, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| CN-113795304-A | Thieno [3,2-B ] pyridin-7-amine compounds for the treatment of familial autonomic nervous dysfunction | PTC医疗公司 | 2021-12-14 | — | — | CN | disclosed |
| WO-2020167628-A1 | THIOENO[3,2-B] PYRIDIN-7-AMINE COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC THERAPEUTICS, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020167628-A1 | THIOENO[3,2-B] PYRIDIN-7-AMINE COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC THERAPEUTICS, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135586-A1 | THIOENO[3,2-B] PYRIDIN-7-AMINE COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | SF3B5, SF3B2, SF3B1 | SMN1; SMN2 42/4885 |
| US-20250382305-A1 | COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | ATXN2, SMN1; SMN2, ATXN10 | SMN1; SMN2 2/4885 |
| US-12384797-B2 | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia | SF3B5, SF3B2, SF3B1 | SMN1; SMN2 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.